%0 Journal Article
%A Díez-Campelo, María
%A Lorenzo, Jose I
%A Itzykson, Raphael
%A Rojas, Silvia M
%A Berthon, Céline
%A Luño, Elisa
%A Beyne-Rauzy, Odile
%A Perez-Oteyza, Jaime
%A Vey, Norbert
%A Bargay, Joan
%A Park, Sophie
%A Cedena, Teresa
%A Bordessoule, Dominique
%A Muñoz, Juan A
%A Gyan, Emmanuel
%A Such, Esperanza
%A Visanica, Sorin
%A López-Cadenas, Félix
%A de Botton, Stéphane
%A Hernández-Rivas, Jesús M
%A Ame, Shanti
%A Stamatoullas, Aspasia
%A Delaunay, Jacques
%A Salanoubat, Celia
%A Isnard, Françoise
%A Guieze, Romain
%A Pérez Guallar, Joan
%A Badiella, Llorenc
%A Sanz, Guillermo
%A Cañizo, Consuelo
%A Fenaux, Pierre
%T Azacitidine improves outcome in higher-risk MDS patients with chromosome 7 abnormalities: a retrospective comparison of GESMD and GFM registries.
%D 2018
%U http://hdl.handle.net/10668/12302
%X Treatment with azacitidine (AZA) has been suggested to be of benefit for higher-risk myelodysplastic syndrome (HR-MDS) patients with chromosome 7 abnormalities (Abn 7). This retrospective study of 235 HR-MDS patients with Abn 7 treated with AZA (n = 115) versus best supportive care (BSC; n = 120), assessed AZA treatment as a time-varying variable in multivariable analysis. A Cox Regression model with time-interaction terms of overall survival (OS) at different time points confirmed that, while chromosome 7 cytogenetic categories (complex karyotype [CK] versus non-CK) and International Prognostic Scoring System risk (high versus intermediate-2) retained poor prognosis over time, AZA treatment had a favourable impact on OS during the first 3 years of treatment compared to BSC (Hazard ratio [HR] 0·5 P 
%K azacitidine
%K chromosome 7 abnormalities
%K high risk MDS
%K time-dependent analysis
%~